Person

Gianni Sava

Related publications (15)

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

, , , ,

Lysozyme is one of the most important anti-bacterial effectors in the innate immune system of animals. Besides its direct antibacterial enzymatic activity, lysozyme displays other biological properties, pointing toward a significant anti-inflammatory effec ...

2019

The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions

Paul Joseph Dyson, Gianni Sava

Platinum drugs are extensively used in the clinic to treat cancer, often leading to a palliative response rather than a cure. While DNA is considered to be the primary target of platinum drugs, there is no clear relationship between cellular platinum accum ...

2018

, , , , ,

Nanoscale secondary ion mass spectrometry (NanoSIMS) combined with transmission electron microscopy (TEM) can be a powerful approach to visualize the exact distribution of drugs at the sub-cellular level. In this work, we exploit this approach to identify ...

2017

, ,

Aim of the study The tumor metastases targeting ruthenium complex NAMI-A synergistically improves the activity of gemcitabine in combination therapies. High-throughput screening was used to identify other potential drug combinations from a library of FDA a ...

Springer2015

Organometallic ruthenium-based antitumor compounds with novel modes of action

Paul Joseph Dyson, Angela Casini, Wee Han Ang, Gianni Sava

Both metal complexes and organic molecules are widely used for the treatment of various diseases including cancer - in addition to surgery and radiotherapy. Recent years have witnessed a surge of interest in the application of organometallic compounds to t ...

2011

Metal-Based Inhibition of Poly(ADP-ribose) Polymerase - The Guardian Angel of DNA

Paul Joseph Dyson, Yury Tsybin, Angela Casini, Alexey Nazarov, Michael Groessl, Gianni Sava

The inhibition activity of a series of anticancer metal complexes based on platinum, ruthenium, and gold metal ions was evaluated on the zinc-finger protein PARP-1, either purified or directly on protein extracts from human breast cancer MCF7 cells. Inform ...

American Chemical Society2011

In our Dalton Transactions Perspective article entitled, 'Metal-based antitumour drugs in the post genomic era', (Dalton Trans., 2006, 1929-1933) we discussed metal-based drugs in light of past decades of research. We concluded that the post-genomic era wo ...

2011

Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound

Paul Joseph Dyson, Gianni Sava

The modulation of the metastatic progression of breast cancer has been evaluated in vitro and in vivo with RAPTA-T, [Ru(η6-toluene)Cl2(PTA)], an organometallic ruthenium compd. In vitro RAPTA-T inhibits some steps of the metastatic process such as the deta ...

2008

Development of Ruthenium Antitumor Drugs that Overcome Multidrug Resistance Mechanisms

Paul Joseph Dyson, Wee Han Ang, Andrew Douglas Phillips, Claudine Scolaro, Gianni Sava

Organometallic ruthenium(II) complexes of the general formula [Ru(η6-p-cymene)Cl2(L)] and [Ru(η6-p-cymene)Cl(L)2][BPh4] with modified phenoxazine- and anthracene-based multidrug resistanc ...

2007

Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy

Paul Joseph Dyson, Christian Hartinger, Claudine Scolaro, Gianni Sava

The antitumor activity of the organometallic ruthenium(II)-arene mixed phosphine complexes, [Ru(h6-p-cymene)Cl(PTA)(PPh3)]BF4 1b and [Ru(h6-C6H5CH2CH2OH)Cl(PTA)(PPh3)]BF4 2b (PTA = 1,3,5-triaza-7-phosphaadamantane), have been evaluated in vitro and compare ...

2007